1 / 14

QUALITY USE OF CARDIOVASCULAR MEDICATION

QUALITY USE OF CARDIOVASCULAR MEDICATION. Dr Mark Abelson. Prescription Drugs and Drug Trials. Drug development - basic science research in a laboratory - chemical patented (20 years) - laboratory testing - Phase 1 trials – tested for safety and efficacy in animals

ismail
Télécharger la présentation

QUALITY USE OF CARDIOVASCULAR MEDICATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. QUALITY USE OF CARDIOVASCULAR MEDICATION Dr Mark Abelson

  2. Prescription Drugs and Drug Trials • Drug development - basic science research in a laboratory - chemical patented (20 years) - laboratory testing - Phase 1 trials – tested for safety and efficacy in animals - Phase 2 trials – tested for safety in normal humans - Phase 3 trials – show effective (better than placebo or current standard treatment) and safe in many thousands of patients around the world (double blind

  3. Drug launched (5 years patent remaining) - post marketing surveillance • $ +100 million • Register with FDA / MCC (years)

  4. “Alternative” Drugs • Vitamins • Minerals • Cholesterol vaporises • Tissue salts NO RESEARCH NO EVIDENCE OF EFFICACY NO PRODUCTION CONTROL NO REGISTRATION PROCESS Trials done consistently show NO benefit eg. Folate, anti-oxidant vitamins

  5. Conspiracy Theory • Doctors and Universities – bribed / kick backs from pharmaceutical companies? • Lack of patient trust? • Only want “natural” treatment ( death?)

  6. Commonly Used Drugs • Statins -reduce cholesterol - Zocor, Simvastatin, Lipitor, Aspavor, Crestor, Prava, Lescol – primary prevention (at risk but currently asymptomatic) benefit in high risk persons or - secondary prevention (known with coronary artery disease) 30% reduction in future heart attack and stroke • Aspirin - reduces blood stickiness – primary (little benefit) or secondary prevention (25% ) • ACE-I / ARB – lower BP, improve heart failure - Prexum, Coversyl, Lisinopril, Zetomax, Pharmapres, Enalapril, Cozaar, Zartan, Diovan

  7. Commonly Used Drugs • Beta Blockers – reduce heart rate (angina) and BP, heart failure - Concor, Bilocor, Bisocor, Carloc, Dilatrend • Calcium Channel blockers – reduce heart rate and BP - Verahexal, Calcicard, Ravamil, Amloc, Norvasc, Zildem

  8. New Comers • Coralin – reduces heart rate without decreasing BP and no BB side effects (lethargy, impotence) - angina and heart failure • Dabigatran – thins blood like Warfarin but no INR (blood) testing needed - atrial fibrillation

  9. Guideline recommendations for BP goals • <140/90mmHg for essential hypertension • <130/80mmHg for hypertensive patients with diabetes • Most patients with hypertension will require two or more antihypertensive agents to achieve BP goal *ESH/ESC: European Society of Hypertension/European Society of Cardiology **JNC 7: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, seventh report Guidelines Committee. J Hypertens 2003; 21: 1011-53. Chobanian AV, et al. JAMA 2003; 289: 2560-72.

  10. Trial/SBP achieved INVEST (136mmHg) ALLHAT (138mmHg) IDNT (138mmHg) RENAAL (141mmHg) UKPDS (144mmHg) ABCD (132mmHg) MDRD (132mmHg) HOT (138mmHg) AASK (128mmHg) 1 2 3 4 Number of antihypertensive drugs Combination therapy needed to achieve target SBP goals INVEST; data on file. ALLHAT Collaborative Research Group. JAMA 2002; 288: 2981-97. Brenner BM, et al. N Engl J Med 2001; 345: 861-9. Lewis EJ, et al. N Engl J Med 2001; 345: 851-60. Adapted from Bakris GL, et al. Am J Kidney Dis 2000; 36: 646-61.

  11. Coronary artery disease Peripheralarterial disease Cardiac failure Stroke 50 Normal 40 Hypertensive 30 Biennial age-adjustedrate per 1000 20 10 0 Women Men Women Men Women Men Women Men Hypertension: a risk factor forcardiovascular morbidity and mortality Risk ratio 2.0 2.2 3.8 2.5 2.0 3.7 4.0 3.0 Excess risk 22.7 11.6 9.1 3.8 4.9 5.3 10.4 4.2 Kannel WB. JAMA 1996; 275: 1571-6.

  12. 300 Non-diabetic Diabetic 250 200 CVD deaths per 10,000 person-years 150 100 50 0 <120 120-139 140-159 160-179 180-199 200+ Systolic BP (mmHg) MRFIT: association of systolic BP and diabetes with cardiovascular risk Stamler J, et al. Diabetes Care 1993; 16: 434-44.

  13. Early morning BP surge coincides with peak incidences of stroke and myocardial infarction Stroke (n=1,167) MI (n=2,999) Early morningBP surge 50 45 40 35 30 25 20 15 10 5 0 180 160 140 120 100 80 60 40 20 0 Cerebrovascular events(per 2 hours) MI (per hour) 18.00 0.00 06.00 12.00 Time of day McInnes G. J Am Soc Hypertens 2008;2:S16–22.

More Related